MEDEZE Group Earns 2025 Company of the Year Award in Southeast Asia

MEDEZE Group Public Company Limited has been awarded the prestigious 2025 Southeast Asia Company of the Year Recognition by Frost & Sullivan for its remarkable contributions to the fields of stem cell banking and regenerative medicine. This accolade, announced on December 15, 2025, underscores the company’s leadership in innovation, regulatory oversight, and clinical integration across the region.

The recognition highlights MEDEZE’s pivotal role in transforming personalized healthcare solutions while adhering to stringent global standards in safety, technology, and compliance. Frost & Sullivan’s evaluation process involved rigorous benchmarking based on two primary dimensions: strategy effectiveness and strategy execution. MEDEZE demonstrated exceptional performance in both areas, aligning its strategic initiatives with market demands and executing them with precision.

Innovation and Growth in Regenerative Healthcare

Unmesh Lal, Vice President of Healthcare & Life Sciences at Frost & Sullivan, stated, “MEDEZE is redefining stem cell banking in Southeast Asia through full-spectrum, clinically aligned solutions.” The company leverages innovation and regulatory leadership, supported by a robust GMP-grade infrastructure, to facilitate the transition from mere cell preservation to personalized medical applications.

MEDEZE employs a vertically integrated model that encompasses various stages: biological material collection, diagnostics, cell processing, storage, expansion, and clinical application. This approach ensures consistent quality and regulatory compliance, catering to the diverse healthcare needs across Southeast Asia.

Central to MEDEZE’s success is its commitment to innovation. The company utilizes proprietary technologies such as the AutoXpress System for fully automated cord blood processing and the Chibuya Robotic Stem Cell Culture System, recognized as the world’s first full-room cleanroom automation. These innovations enable therapeutic-grade manufacturing on a large scale. Additionally, MEDEZE’s AI-powered Hair Follicle Restoration platform and exclusive NK cell diagnostic technologies from Japan illustrate its capacity to broaden cell applications into both clinical and aesthetic care.

Certifications and Future Aspirations

MEDEZE’s dedication to achieving international accreditation strengthens its position in the regenerative medicine sector. It is notably the only Thai stem cell bank accredited by the Association for the Advancement of Blood & Biotherapies (AABB) and holds ISO 9001 and ISO 22716 certifications. These credentials affirm the company’s compliance with the highest safety and quality standards in therapeutic and wellness applications.

With support from a network of over 260 hospital partners, including renowned institutions like Samitivej Hospital Group and Bangkok Hospital, MEDEZE is playing a crucial role in Thailand’s ADMP Sandbox clinical program. The company is actively engaged in trials addressing conditions such as osteoarthritis, degenerative disc disease, skin rejuvenation, colorectal cancer, and immune enhancement. By 2026, MEDEZE aims to be among the first private firms in Southeast Asia to commercialize licensed cell therapies.

Frost & Sullivan commends MEDEZE for setting new standards in competitive strategy and market responsiveness. The company’s integrated operational model, financial strength, and commitment to sustainable growth exemplify its leadership in biotechnology. Each year, Frost & Sullivan honors organizations that excel in strategy development and execution, resulting in significant improvements in market share, customer satisfaction, and competitive positioning.

The Frost & Sullivan Best Practices Recognition highlights companies that achieve exceptional results in leadership, technological innovation, customer experience, and strategic product development. This recognition process involves thorough analysis and benchmarking by industry experts, aiming to identify organizations that are driving transformative growth and establishing new industry standards.

MEDEZE Group’s recognition not only reinforces its status as an innovator in regenerative healthcare but also positions it as a leader in the ongoing evolution of personalized medical solutions in Southeast Asia.